N
Natera
Harnessing the power of DNA to improve the management of reproductive health, cancer, and organ transplants
At a glance
- Status
- Listed
- Listing
- IPO 2015
Open roles
Natera in the Austin ecosystem
The Natera office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Sequoia- CVClaremont Creek Ventures
Series B and later11 investors entered at this stage
Foresite Capital
Founders Fund- HPHealthCor Partners
Franklin Templeton Investments- SISofinnova Investments
Lightspeed Venture Partners- ACAlafi Capital
- JAJennison Associates
- HPHarmony Partners
RA Capital Management
OrbiMed
Source: Dealroom Talent Intelligence.
Alumni founders
Former Natera employees who went on to found companies, sorted by Dealroom signal score.
DADatavantEst. 2017
Sam RooszUnited States
GIGigaGenEst. 2010
David JohnsonUnited States
Jonathan SheenaUnited States
CBCurve BiosciencesEst. 2021
Nathan HunkapillerUnited States
STSilverback TherapeuticsEst. 2016
Badreddin EdrisUnited StatesPatents
59 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Natera was the backer or acquirer, 2022–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
2 deals across Natera's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Where Natera deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
Natera's portfolio, mapped.
See Natera on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
iMDx launches second stock offering of 2026 to fund transplant test push
Natera wins FDA Breakthrough Device designation for multi-cancer early detection blood test
